FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine
October 07, 2019 17:57 ET
|
FibroGen, Inc
SAN FRANCISCO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) is pleased to announce that William G. Kaelin, Jr., who serves on the company’s Scientific Advisory Board, has been...
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy
September 26, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class...
The New England Journal of Medicine (NEJM) Publishes Roxadustat China Phase 3 Results for the Treatment of Anemia in Chronic Kidney Disease Patients Receiving Dialysis
July 24, 2019 18:53 ET
|
FibroGen, Inc
-- One of Two Concurrent Publications of Roxadustat China Phase 3 Results in The New England Journal of Medicine -- SAN FRANCISCO, July 24, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN)...
Europe Blood and Blood Components Market to hit $5 billion by 2024: Global Market Insights, Inc.
June 19, 2019 01:00 ET
|
Global Market Insights, Inc
Selbyville, Delaware, June 19, 2019 (GLOBE NEWSWIRE) -- Russia blood and blood components market is estimated to witness fastest growth to reach USD 840 million by 2024. Growing geriatric...
Trivedi Global, Inc. Announces Research by Alice Branton on Energy Treated Iron to Potentially Provide a Formulation Which Provides a Better Therapeutic Response to Anemia.
April 19, 2019 10:00 ET
|
Trivedi Global, Inc.
Las Vegas, NV, April 19, 2019 (GLOBE NEWSWIRE) -- Alice Branton, an evidence-based healer, today released research results on the beneficial impact of biofield energy treatment on improving...
New American Kidney Fund Survey Highlights Importance of Patient-Practitioner Discussions About Anemia
February 04, 2019 12:29 ET
|
American Kidney Fund
Rockville, MD, Feb. 04, 2019 (GLOBE NEWSWIRE) -- A new survey by the American Kidney Fund (AKF) shows gaps in patient awareness and understanding of anemia, a serious health condition that is a...
Blood and Blood Components Market worth over $43.5 Billion by 2024: Global Market Insights, Inc.
January 07, 2019 05:00 ET
|
Global Market Insights, Inc
Sellbyville, Delaware, Jan. 07, 2019 (GLOBE NEWSWIRE) -- U.S. blood and blood components market dominated the global industry with more than 35% market share in 2017. Rising number of surgeries...
FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease
December 20, 2018 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today...
FibroGen Reports Third Quarter 2018 Financial Results
November 08, 2018 16:02 ET
|
FibroGen, Inc
—Roxadustat New Drug Applications under Review in China and Japan——Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019——Conference Call Today at 5:00 p.m. Eastern...
FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting
October 16, 2018 16:27 ET
|
FibroGen, Inc
Roxadustat Phase 3 Clinical Results in Late-Breaking Clinical Trial Posters and Oral Presentation SAN FRANCISCO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading...